Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism

Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism

Background: Arterial stiffness is linked to the progression of atherosclerosis, while activation of vitamin D receptor exerts favorable cardiovascular effects in patients with renal insufficiency. In this study, we investigated the effects of oral treatment with paricalcitol, a potent vitamin D rece...

Full description

Bibliographic Details
Main Authors:	Michalis Giakoumis, Costas Tsioufis, Kyriakos Dimitriadis, Makro Sonikian, Alexandros Kasiakogias, Eirini Andrikou, Theodoros Kalos, Dimitrios Konstantinidis, Konstantinos Filis, Dimitrios Petras, Dimitrios Tousoulis
Format:	Article
Language:	English
Published:	Elsevier 2019-03-01
Series:	Hellenic Journal of Cardiology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1109966617305043

Similar Items

The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the “Ariadne's thread” for the “labyrinth” of COVID-19
by: Costas Tsioufis, et al.
Published: (2020-01-01)

Do we need biomarkers for diabetics progressing to heart failure?
by: Kyriakos Dimitriadis, et al.
Published: (2018-03-01)

The new guidelines for hypertension: Navigating between Scylla and Charybdis of clinical practice
by: Costas Tsioufis, et al.
Published: (2020-03-01)

GLP-1 receptor agonists and cardiovascular outcome trials: An update
by: Eirini Andrikou, et al.
Published: (2019-11-01)

Renal Functional Reserve Is Related to the Nondipping Phenotype and to the Exercise Heart Rate Response in Patients with Essential Hypertension and Preserved Renal Function
by: Katerina Damianaki, et al.
Published: (2020-08-01)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
by: Josep M. Cruzado, et al.
Published: (2018-01-01)

The concept of “preventive” interventional cardiology: from imaging to stenting and beyond
by: Kyriakos Dimitriadis, et al.
Published: (2022-01-01)

Successful left transradial coronary angiography in an elderly patient with dextrocardia and severe aortic stenosis
by: Konstantinos Kintis, et al.
Published: (2017-11-01)

DIAGNOSIS AND TREATMENT OF PATIENTS WITH SECONDARY HYPERPARATHYROIDISM AND RENAL INSUFFICIENCY. THERAPEUTIC POTENTIAL OF PARICALCITOL
by: Zh. E. Belaya, et al.
Published: (2018-01-01)

Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism
by: Francisco José Borrego Utiel, et al.
Published: (2015-07-01)

An ECG Diagnosis Only for the Cold-Hearted
by: Anastasios Milkas, et al.
Published: (2016-01-01)

Renal denervation vascular effects: An “insider's” view
by: Kyriakos Dimitriadis, et al.
Published: (2020-05-01)

SPYRAL HTN-OFF MED study: Renal denervation in the spiral orbits of current results and future studies
by: Costas Tsioufis, et al.
Published: (2017-09-01)

Budget impact analysis of the use of paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease
by: Valentina Lorenzoni, et al.
Published: (2014-09-01)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
by: Daniela Ponce, et al.
Published: (2023-04-01)

Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
by: Brandi Lisbet, et al.
Published: (2009-09-01)

Selective vitamin D receptor activator Paricalcitol and its potential benefits in hemodialysis patients with secondary hyperparathyroidism
by: L. V. Egshatyan
Published: (2022-06-01)

Comparison of Paricalcitol (I.V) and Alfacalcidol (I.V) in Treatment of Secondary Hyperparathyroidism (SHPT) in Hemodialysis Patients
by: Mansoor Abbas Qaisar, et al.
Published: (2020-12-01)

Effectiveness and Safety of Ultrasound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study
by: Shuqin Xie, et al.
Published: (2022-11-01)

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
by: Marilia Mastrocolla de Almeida Cardoso, et al.
Published: (2022-08-01)

A network meta-analysis of the antithrombotic strategies in patients with atrial fibrillation and percutaneous coronary interventions: Focus on bleeding
by: Kyriakos Dimitriadis, et al.
Published: (2023-09-01)

Design of novel screening environments for Mild Cognitive Impairment: giving priority to elicited speech and language abilities
by: Ioannis Paliokas, et al.
Published: (2015-11-01)

Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison
by: Jacek Zawierucha, et al.
Published: (2019-02-01)

A Narrative Review on Exercise and Cardiovascular Events: “Primum Non Nocere”
by: Kyriakos Dimitriadis, et al.
Published: (2022-01-01)

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials
by: Yifeng Xie, et al.
Published: (2017-08-01)

The subcutaneous ICD as an alternative to the conventional ICD system: Initial experience in Greece and a review of the literature
by: Skevos Sideris, et al.
Published: (2017-01-01)

Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias
by: Charalambos Vlachopoulos, et al.
Published: (2019-03-01)

P1668: NON-APOPTOTIC CIRCULATING MICROPARTICLES ARE INVERSELY ASSOCIATED WITH PROCOAGULANT BIOMARKERS IN PATIENTS WITH ACUTE CORONARY SYNDROMES
by: Zoi Pallantza, et al.
Published: (2023-08-01)

Naxos disease patient with sustained ventricular tachycardia and multifocal thrombi in the right ventricle: Concerns on therapeutic management
by: Eirini Dri, et al.
Published: (2021-11-01)

Scanning of Genetic Variants and Genetic Mapping of Phenotypic Traits in Gilthead Sea Bream Through ddRAD Sequencing
by: Dimitrios Kyriakis, et al.
Published: (2019-08-01)

A Viewpoint on the Challenges and Solutions for Driverless Last-Mile Delivery
by: Vasiliki Balaska, et al.
Published: (2022-11-01)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
by: Izquierdo María, et al.
Published: (2012-11-01)

The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism
by: Jesús Egido, et al.
Published: (2016-01-01)

Anti-inflammatory profile of paricalcitol in kidney transplant recipients
by: Javier Donate-Correa, et al.
Published: (2017-11-01)

Simultaneous repair of a post-infarction ventricular septal rupture and left ventricular aneurysm: A modified double patch technique
by: Nikolaos Koumallos, et al.
Published: (2022-07-01)

Hypertensive urgencies during the first wave of the COVID-19 pandemic in a tertiary hospital setting: a U-shaped alarming curve
by: Ioannis Leontsinis, et al.
Published: (2021-09-01)

The Contemporary Role of Speckle Tracking Echocardiography in Cirrhotic Cardiomyopathy
by: Yannis Dimitroglou, et al.
Published: (2024-01-01)

Transcatheter edge-to-edge repair in an octogenarian patient with massive tricuspid regurgitation: Release of the pseudoconstriction pattern and improvement in the right ventricular hemodynamics
by: Charalampos Kalantzis, et al.
Published: (2023-03-01)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
by: María Dolores Arenas Jimenez, et al.
Published: (2021-07-01)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
by: Luis D’Marco, et al.
Published: (2022-12-01)